MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.schres.2019.07.055

Медицинская библиотека · Schizophrenia research · 2019

Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.

Iwata Nakao, Ishigooka Jun, Kim Won-Hyoung, Yoon Bo-Hyun, Lin Shih-Ku, Sulaiman Ahmad Hatim, Cosca Rowena, Wang Lina, Suchkov Yury, Agarkov Alexey, Watabe Kei, Matsui Tomohito, Sato Takayuki, Inoue Yoshifumi, Higuchi Teruhiko, Correll Christoph U, Kane John M

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia. This study determined the efficacy, safety and pharmacokinetics of a blonanserin transdermal patch in patients with acutely exacerbated schizophrenia.

METHODS

This double-blind, multicenter, phase 3 study consisted of a 1-week observation period during which patients were treated with two patches of placebo, followed by a 6-week double-blind period where patients were randomized (1:1:1) to receive once-daily blonanserin 40 mg, blonanserin 80 mg, or placebo patches. The primary endpoint was the change from baseline in the total Positive and Negative Symptom Scale (PANSS) score. Safety assessments included treatment-emergent adverse events (TEAEs).

RESULTS

Between December 2014 and October 2018, patients were recruited and randomly assigned to blonanserin 40 mg (n = 196), blonanserin 80 mg (n = 194), or placebo (n = 190); of these, 77.2% completed the study. Compared with placebo, blonanserin significantly improved PANSS total scores at 6 weeks (least square mean [LSM] difference vs placebo: -5.6 with blonanserin 40 mg; 95% confidence interval [CI] -9.6, -1.6; adjusted p = 0.007, and - 10.4 with blonanserin 80 mg; 95% CI -14.4, -6.4; adjusted p < 0.001). Blonanserin was well tolerated; the most common TEAEs reported were application-site erythema and pruritus, akathisia, tremor, and insomnia.

CONCLUSIONS

Blonanserin transdermal patch improved the symptoms of acute schizophrenia with acceptable tolerability.

Для цитирования: Iwata Nakao, Ishigooka Jun, Kim Won-Hyoung, Yoon Bo-Hyun, Lin Shih-Ku, Sulaiman Ahmad Hatim, Cosca Rowena, Wang Lina, Suchkov Yury, Agarkov Alexey, Watabe Kei, Matsui Tomohito, Sato Takayuki, Inoue Yoshifumi, Higuchi Teruhiko, Correll Christoph U, Kane John M. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.. Schizophrenia research. 2019. DOI: 10.1016/j.schres.2019.07.055.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.